Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Once-daily 14 mg oral semaglutide yields greater reduction in HbA1c and body weight than weekly 0.75 mg subcutaneous dulaglutide and is well tolerated in a Japanese population with uncontrolled type 2 diabetes (T2D), according to the PIONEER 10 study.
Condomless anal intercourse (CAI), even among serodiscordant (SD-CAI) participants, is common among young, gay, bisexual, and other men who have sex with men (YGBMSM) living with HIV with detectable viral loads, a recent study has shown.
There is a high incidence of psychiatric comorbidities among gender nonconforming teenagers, with about two-thirds and one-third experiencing depression and anxiety, respectively, according to a study presented at ENDO 2020.
More men than women die from SARS-CoV-2 infection, although it remains uncertain whether this difference is driven by biological dissimilarities between the sexes, or disparities in behavioural habits or in rates of comorbidities, according to a study.
Treatment with 15 mCi of radioiodine (RAI) leads to low hypothyroidism rates in adult patients with toxic multinodular goiter (TMNG), with high cure rates and significant volume reduction, according to a study. This effect persists in the long term.
Older Singaporeans with limited English health literacy (EHL) are more likely to report uncertainty as regards taking medications correctly compared with those with adequate EHL, according to a study. Elderly people with limited EHL have difficulty understanding the information on prescription medication labels (PMLs), which then contributes to medication nonadherence.
The glucagon-like peptide-1 (GLP-1) receptor agonist (RA) dulaglutide shows highly consistent effectiveness on glycated haemoglobin (HbA1c) and body weight reduction in patients with type 2 diabetes (T2D), reveals a study. Its effectiveness remains significant even in subgroups of patients poorly represented in randomized controlled trials (RCTs).
Special Reports
At a GSK-sponsored symposium during the 15th Asian & Oceanian Congress of Child Neurology 2019, held in conjunction with the 41st Malaysian Paediatric Association Annual Congress at Shangri-La Hotel Kuala Lumpur, Dato’ Dr Musa Mohd Nordin spoke about the current state of VPDs and expounded the value of combination vaccines in mitigating the risk of infectious disease transmission in the paediatric population.
At the 13th Annual Scientific Meeting of the Malaysian Osteoporosis Society (MOS), Dr Chan Siew Pheng discussed the role of alfacalcidol (One-Alpha®) in the treatment of osteoporosis (OP) and presented several patient profiles where alfacalcidol exhibited efficacy in increasing bone mineral density (BMD).
This second issue revisits the impact EMPA-REG OUTCOME had on clinical
practice and helps readers discover how it gives life back to patients
through its cardiovascular indication. Learn how it was approved and the
possible
mechanisms for its cardiovascular benefits.
Heart failure (HF) is a global public health concern, affecting about 38 million individuals globally.1 Several studies suggest a rising prevalence of HF, which could be attributed to the ageing of the population, along with improved HF survival owing to the tremendous advancement in HF therapy.2–4 In this case study, Dato’ Dr Ahmad Murtazam shares his clinical experience in managing a patient with HF and reduced ejection fraction (HFrEF), following acute myocardial infarction (AMI) and multiple hospitalisations.
Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.
Among patients undergoing complex percutaneous coronary intervention (PCI) who completed 3 months of dual antiplatelet therapy (DAPT) comprising aspirin and the potent P2Y12-receptor inhibitor ticagrelor, aspirin withdrawal led to fewer bleeding episodes without increasing the risk of ischaemic events compared with continued DAPT, according to data from the TWILIGHT-COMPLEX* subanalysis presented at ACC.20/WCC Virtual.
Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.
Conference Reports
Combining the oral GnRH* receptor antagonist relugolix together with oestradiol and the progestin norethindrone helps protect against bone loss induced by oestrogen deprivation associated with the use of GnRH receptor antagonist monotherapy for treating heavy menstrual bleeding, according to the LIBERTY studies released during ACOG 2020 Meeting.
The addition of the oral GnRH* antagonist elagolix to hormonal add-back therapy (E2/NETA**) reduces menstrual blood loss (MBL) in women with heavy menstrual bleeding (HMB) associated with uterine fibroids (UF) and comorbid adenomyosis, with the extension phase showing benefits beyond 6 months, according to data presented at ACOG 2020.
A study from South Korea, presented at ENDO 2020, suggested that individuals who work long hours may be at risk of developing hypothyroidism.
A once-weekly tuberculosis (TB) prevention regimen of isoniazid 900 mg and rifapentine 900 mg given for 3 months (3HP) resulted in higher treatment completion rates vs isoniazid daily for 6 months (6H) in patients with HIV receiving antiretroviral therapy (ART), a study released at CROI 2020 has shown.
The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates.
A novel, investigational vaginal pH regulator (VPR) – a nonhormonal, water-based, petroleum-free contraceptive vaginal gel – improved genitourinary (GU) side effects and sexual satisfaction in women who are at risk of pregnancy but are not aiming to conceive, interim findings from the phase III AMPOWER* trial show.
A levonorgestrel (LNG)-releasing intrauterine device (IUD) maintains high contraceptive efficacy up to 6 years, which is beyond the 5-year period it is currently approved for, according to data from the Mirena Extension Trial (MET) released during the ACOG 2020 Meeting.
Multimedia
